Compounded tirzepatide

Compounded Tirzepatide Tracker

Engineered for compounded tirzepatide vials. Convert mg to syringe units across 10 mg/mL, 20 mg/mL, and custom concentrations, model 5-day dual-agonist half-life curves, and forecast reorder dates on iOS.

10 & 20 mg/mLSupports all high-concentration compounded tirzepatide vials
5 daysActive dual GIP/GLP-1 half-life curve modeled in real time
10-day alertReorder warning ensures you never experience a telehealth supply gap
100% privateOn-device iOS storage with zero account creation
⚡ 30-Second Verdict Compounded Tirzepatide Syringe & Dose Engine

GLPme is a dedicated tracking and calculation app built for compounded tirzepatide patients. Managing multi-dose tirzepatide vials (10 mg/mL, 20 mg/mL, and custom peptide reconstitution) with insulin syringes requires exact concentration math. GLPme translates prescribed milligrams into syringe units, graphs your 5-day half-life decay, tracks injection site rotation, and monitors weight loss progress without subscriptions.

Key takeaways

  • Precision syringe conversion: maps compounded tirzepatide mg to syringe units across 10 mg/mL, 20 mg/mL, and custom vials.
  • Visual confirmation prevents concentration mix-ups between starting doses (2.5 mg) and maintenance doses (15 mg).
  • Tirzepatide 5-day half-life graph reveals active blood levels and predicts end-of-week hunger return.
  • Vial supply forecasting warns you when your vial is running low to prevent missed injection weeks.
  • 100% on-device private logging on iOS: zero accounts, zero trackers, zero data sharing.

Compounded tirzepatide: The syringe calculation challenge

Compounded tirzepatide is dispensed in diverse concentrations — most commonly 10 mg/mL, 20 mg/mL, or concentrated blends containing vitamin B12 or glycine. Because tirzepatide doses range widely from 2.5 mg up to 15 mg, drawing medication with a U-100 insulin syringe requires flawless arithmetic.

A mistake of 10 syringe units can mean under-dosing by half or accidentally doubling a dose, resulting in severe gastrointestinal distress. GLPme provides a failsafe visual confirmation: simply select your vial strength and your prescribed dose, and the app shows the exact syringe volume to draw.

Compounded Tirzepatide Companion
Safe, verified syringe conversions on iPhone
Download GLPme free on the App Store. Convert mg to syringe units, track multi-dose vials, and graph active levels offline.
📱 Get GLPme on the App Store →

Syringe unit conversion matrix

Here is how common compounded tirzepatide doses translate on a standard U-100 syringe:

Compounded tirzepatide mg to syringe units on a U-100 syringe (100 units = 1.0 mL).
Dose10 mg/mL Vial20 mg/mL Vial25 mg/mL Vial
2.5 mg25 units (0.25 mL)12.5 units (0.125 mL)10 units (0.10 mL)
5.0 mg50 units (0.50 mL)25 units (0.25 mL)20 units (0.20 mL)
7.5 mg75 units (0.75 mL)37.5 units (0.375 mL)30 units (0.30 mL)
10.0 mg100 units (1.00 mL)50 units (0.50 mL)40 units (0.40 mL)
12.5 mg125 units (Requires 2 syringes)62.5 units (0.625 mL)50 units (0.50 mL)
15.0 mg150 units (Requires 2 syringes)75 units (0.75 mL)60 units (0.60 mL)

Check any custom concentration in seconds on our free tirzepatide units calculator.

Modeling tirzepatide's 5-day half-life curve

Tirzepatide has an elimination half-life of 5 days (120 hours). At steady state, weekly injections produce a predictable wave: concentration peaks at 24 to 48 hours post-injection, and decays by roughly 60% by Day 7. GLPme graphs this pharmacokinetic reality so you can anticipate appetite shifts and coordinate your injection timing with your weekly schedule.

Vial supply and reorder forecasting

Compounded telehealth pharmacies frequently require 7 to 14 business days to compound, quality-test, and ship a replacement vial. GLPme's vial tracker calculates your remaining volume based on logged doses and alerts you 10 days before your vial runs dry, ensuring you never face an unexpected supply gap.

Sources

Every figure on this page traces to one of these. Regulatory documents and peer-reviewed primary research only — see our editorial policy for what we accept as a source.

  1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022. View source
  2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med, 2021. View source
  3. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products. FDA MedWatch, 2024. View source
  4. GLP-1 Agonists: What They Are, How They Work & Side Effects. Cleveland Clinic. View source

Download GLPme for Compounded Tirzepatide

Track your doses, convert syringe units, and monitor active levels on iPhone without subscriptions.

Download on the App Store

Keep reading

Free GLP-1 Companion App Half-life curves • Injection tracker
Get Free →